Xiaohong Yu

Xiaohong Yu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2023 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Open access
XZXinxin Zhang
Xinxin Zhang
NWNing Mm Wang
Ning Mm Wang
PFPeng Mm Fu
Peng Mm Fu
YAYanliang Mm An
Yanliang Mm An
FSFangfang Msc Sun
Fangfang Msc Sun
YLYing Liu
Ying Liu
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, accounting for 50% of all heart failure patients, and is associated with significant mortality. Sodium–glucose cotransporter subtype inhibitor (SGLT2i) is recommended in the AHA and ESC guidelines for the treatment of HFpEF, but the mechanism of SGLT2i to prevent and treat cardiac remodeling and dysfunction is currently unknown, hindering the understanding of the pathophysiology of HFpEF and the development of novel therapeutics. HFpEF model was induced by a high-fat diet (60% calories from lard) + N[w]-nitro-l-arginine methyl ester (l-NAME—0.5 g/L) (2 Hit) in male Sprague Dawley rats to effectively recapture the myriad phenotype of HFpEF. This study's results showed that administration of dapagliflozin (DAPA, SGLT2 inhibitor) significantly limited the 2-Hit–induced cardiomyocyte hypertrophy, apoptosis, inflammation, oxidative stress, and fibrosis. It also improved cardiac diastolic and systolic dysfunction in a late-stage progression of HFpEF. Mechanistically, DAPA influences energy metabolism associated with fatty acid intake and mitochondrial dysfunction in HFpEF by increasing β-hydroxybutyric acid (β-OHB) levels, directing the activation of citrate synthase, reducing acetyl coenzyme A (acetyl-CoA) pools, modulating adenosine 5′-triphosphate production, and increasing the expression of mitochondrial oxidative phosphorylation system complexes I-V. In addition, following clinical DAPA therapy, the blood levels of β-OHB and citrate synthase increased and the levels of acetyl-CoA in the blood of HFpEF patients decreased. SGLT2i plays a beneficial role in the prevention and treatment of cardiac remodeling and dysfunction in HFpEF model by attenuating cardiometabolic dysregulation.

22 January 2015 in Apoptosis
Verified
Journal Article
Closed access
PDF file
HYHui Yang
Hui Yang
NLNan Li
Nan Li
LSLi-Na Song
Li-Na Song
LWLei Wang
Lei Wang
CTCui Tian
Cui Tian
HWHongxia Wang
Hongxia Wang

5 November 2024 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Open access
PDF file
JHJia-Kang He
Jia-Kang He
XJXiao-Xiao Jiang
Xiao-Xiao Jiang
SDShi-Yu Dai
Shi-Yu Dai
XHXiao- Han
Xiao- Han
QZQian-Qiu Zhu
Qian-Qiu Zhu
XYXiaohong Yu
Xiaohong Yu
The incidence of atrial fibrillation (AF) increases with age; however, the precise mechanisms by which aging elevates AF risk and the effective biomarkers for managing AF in elderly patients remain unclear. We analyzed plasma samples from 100 elderly AF patients, 100 young and 100 elderly patients without atrial fibrillation (NAF), along with left atrial tissues obtained from both AF and NAF patients following valve replacement. Our findings indicate reduced levels of β-OHB and citrate synthase (CS) activity in elderly AF patients compared to their NAF counterparts. Statistical analysis revealed a protective association between β-OHB and CS activity concerning the occurrence of elderly AF. Furthermore, atrial tissues from elderly AF patients exhibited mitochondrial dysfunction, structural remodeling, and low-voltage areas. These results suggest that dysregulation of β-OHB levels and CS activity may contribute to aging-related AF by affecting mitochondrial function and atrial remodeling, highlighting their potential as diagnostic biomarkers for this condition. Graphical Abstract

4 January 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JHJian He
Jian He
DXDengyue Xu
Dengyue Xu
LWLu Wang
Lu Wang
XYXiaohong Yu
Xiaohong Yu
Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays an important role in treating conditions such as inflammation, endothelial injury and tumors, and we speculated that Farrerol may also play an important role in mitigating cardiac hypertrophy and remodeling. We established a model of myocardial remodeling using Angiotensin II (Ang II) with concurrent intraperitoneal injection of Farrerol as an intervention. We used cardiac ultrasound, immunohistochemistry, Immunofluorescence, Wheat Germ Agglutinin, Dihydroethidium, Western Blot, qPCR and other methods to detect the role of Farrerol in cardiac remodeling. The results showed that Farrerol inhibited Ang II-induced cardiac hypertrophy; decreased the ratio of heart weight to tibia length in mice; reduced inflammation, fibrosis, and oxidative stress; and reduced the size of cardiomyocytes in vivo. Farrerol inhibited Ang II-induced cardiomyocyte hypertrophy, levels of oxidative stress, and the proliferation and migration of fibroblast in vitro. Our results revealed that Farrerol could inhibit Ang II-induced cardiac remodeling. Farrerol may therefore be a candidate drug for the treatment of myocardial remodeling.

14 August 2025 in Clinical Science
Verified
Journal Article
Open access
CLChao Li
Chao Li
XHXiao Han
Xiao Han
JHJiakang He
Jiakang He
STSheng-Xing Tang
Sheng-Xing Tang
YZYUNLONG ZHANG
YUNLONG ZHANG
LGLianjun Gao
Lianjun Gao
Heart failure with preserved ejection fraction (HFpEF) represents the initial phase of cardiac dysfunction associated with type 2 diabetes mellitus (T2DM). To date, the pathophysiological mechanisms underlying T2DM-induced HFpEF are complex and elusive. Fibroblast activation protein (FAP) is a prolyl-specific serine protease that its inhibition or vaccination has been shown to enhance cardiac repair following myocardial infarction (MI). However, the role and underlying molecular mechanisms by which abnormal FAP activity promotes the development of T2DM-induced HFpEF remain to be elucidated. In this study, the plasma activity and level of FAP were significantly higher in the T2DM with HFpEF group compared to the healthy control group. Moreover, plasma FAP activity and level were positively correlated with the likelihood of T2DM with HFpEF. To investigate the mechanistic involvement of FAP in the development of T2DM-associated HFpEF, a chronic T2DM mouse model was established. The results revealed that FAP KO significantly improved BNP level and E/A ratios compared to the WT T2DM group. Additionally, FAP KO and FAP inhibitor Talabostat alleviated myocardial inflammation, fibrosis, cardiomyocyte apoptosis, oxidative stress and energy metabolism dysfunction. Mechanistically, abnormal increase FAP triggered the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway, leading to the aforementioned pathological changes in T2DM-induced HFpEF. In contrast, FAP KO suppressed the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway and attenuated these pathological changes. Overall, these findings suggest that FAP may serve as a critical therapeutic target for T2DM-induced HFpEF.

7 May 2025 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
ZZZhipeng Zhang
Zhipeng Zhang
ZWZonglei Wu
Zonglei Wu
CLChao Luan
Chao Luan
SDShiyu Dai
Shiyu Dai
FCFeiFei Chen
FeiFei Chen
XYXiaohong Yu
Xiaohong Yu
Aims: Long-term complications occur in approximately 4%–12% of patients with standard transvenous pacemakers (TVPs), most of whom are elderly. The leadless pacemaker (LP) has emerged as an effective alternative to traditional TVPs, offering a lower complication profile. However, data on LP implantation in octogenarians remain limited, and concerns persist regarding its feasibility and safety in this population. This study aimed to assess the feasibility and clinical outcomes of LP implantation in octogenarians.Methods and Results: Between January 2021 and January 2024, 154 patients (mean age 75.5 ± 9.8 years) who underwent LP implantation at our center were consecutively included. The study cohort was stratified into two age groups: octogenarians (≥80 years, mean age 84.2 ± 3.3 years, n = 66) and non-octogenarians (<80 years, mean age 69.0 ± 7.9 years, n = 88). Outcomes assessed included electrical parameters, procedural characteristics, and complication rates at hospital discharge and throughout the follow-up period. The procedure was successfully performed in all patients. Six patients (five octogenarians and one non-octogenarian) underwent LP implantation along with concurrent removal of transvenous pacing systems due to prior pocket infections. No device-related infections were observed. LP implantation combined with atrioventricular node ablation (AVNA) was successfully performed in three octogenarians without any complications. Despite having a higher burden of comorbidities, as indicated by a higher age-adjusted Charlson Comorbidity Index (7 IQR 5–8 vs. 4 IQR 3–6, p < 0.001),the octogenarian group demonstrated comparable outcomes to the non-octogenarians. No statistically significant differences were observed between the groups regarding electrical parameters, procedure duration, fluoroscopy time during a median follow-up of 12 (IQR 6–22) months. The proportion of patients requiring more than two deployment attempts was significantly higher among octogenarians (48.5% vs. 26.1%, p = 0.032). These findings suggest that LP implantation is safe and effective in octogenarians when performed at experienced centers. However, the incidence of significant periprocedural complications was relatively higher in octogenarians than in non-octogenarians (4.5% vs. 1.1%), although this difference was not statistically significant.Conclusions: LP implantation appears to be a safe and effective therapeutic option for octogenarians, including those with more combabilities. Therefore, it should be considered a viable alternative to conventional TVPs in this aging population.